STOCK TITAN

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced a business update conference call and webcast to discuss operational updates, growth strategy, and financial results for the fourth quarter and full year 2023.
Positive
  • None.
Negative
  • None.

Conference Call and Webcast at 8:30AM Eastern Time

NEW YORK, March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 26, 2024, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth-quarter and full year 2023 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-a-business-update-conference-call-and-webcast-on-march-26-2024-302086643.html

SOURCE Lucid Diagnostics

Lucid Diagnostics Inc. will host the business update conference call and webcast on Tuesday, March 26, 2024, at 8:30 AM ET.

Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide the business update.

Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's fourth-quarter and full year 2023 financial results.

Listeners can access the webcast at the investor relations section of the Company's website at luciddx.com.

U.S.-based callers should dial 1-800-836-8184 to access the conference call by telephone.

A replay of the conference call will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
Lucid Diagnostics Inc

NASDAQ:LUCD

LUCD Rankings

LUCD Latest News

LUCD Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing